RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Fusion Antibodies Stock

Fusion Antibodies Employees 2024

Fusion Antibodies Employees

47

Ticker

FAB.L

ISIN

GB00BDQZGK16

In 2024, Fusion Antibodies employed 47 people, a 0% change from the 47 number of employees in the previous year.

Fusion Antibodies Aktienanalyse

What does Fusion Antibodies do?

The company Fusion Antibodies PLC is a biotechnology company specializing in the production of antibodies for medical and scientific research. The company, based in Belfast, Northern Ireland, was founded in 2001 and has been listed on the London Stock Exchange since 2017. Fusion Antibodies' business model is based on the development of customized antibodies for customers in the pharmaceutical, biotech, diagnostics, and academic research sectors. The company offers a wide range of services throughout the entire antibody development process, from antigen design to the production of recombinant antibodies and antibody conjugates. Fusion Antibodies divides its business operations into three main departments: antibody engineering, antibody production, and antibody conjugation. The antibody engineering department is involved in the discovery and optimization of antibodies using advanced technologies such as phage display and hybridoma technologies. In the antibody production department, the desired antibodies are produced through cell culture or recombinant technologies. Finally, in the antibody conjugation department, the antibody is coupled with other molecules such as enzymes, toxins, or fluorescent dyes to generate new therapeutic agents or diagnostic systems. Fusion Antibodies also offers a variety of products that can be either individually configured by customers or purchased as standard products. The portfolio of standard products includes antibodies against known target molecules such as GFP, His-tag, and HA-tag, as well as antibodies tailored to specific applications such as anti-idiotypic antibodies or antibodies for the detection of posttranslational modifications of proteins. In addition, Fusion Antibodies also offers a customized service for the production of antibodies against customer-specific target molecules, tailored to the individual needs of the customer. Fusion Antibodies has numerous customers from the biopharmaceutical and biotechnology industry, as well as from academic research. The company works closely with its customers to meet their specific requirements and offers flexibility and a creative approach through its technology platform in developing solutions for their challenges. The company has a strong R&D department and continuously invests in the development of new technologies and products to maintain and expand its competitiveness. Fusion Antibodies also has partnerships with other companies and institutions in the biotech industry to jointly develop new technologies and products. Overall, Fusion Antibodies is an innovative company specializing in the development of antibodies for use in medical and scientific research. Through its wide range of services, products, and partnerships, the company has solidified its position in the biotech industry and is expected to continue to play an important role in the development of new therapeutic and diagnostic approaches. Fusion Antibodies ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Employees Details

Examining Fusion Antibodies's Employee Base

Fusion Antibodies's employees are a pivotal aspect of its operations, driving innovation, productivity, and growth. The size and composition of the workforce offer insights into the company's scale, diversity, and investment in human capital. Analyzing employee trends and data is essential for understanding Fusion Antibodies's operational capacity and future potential.

Year-to-Year Comparison

Assessing Fusion Antibodies's employee numbers year-over-year helps in identifying growth patterns, expansions, or contractions. An increasing employee count can indicate scaling operations and investment in talent, while a decrease may signal efficiency improvements, automation, or business challenges.

Impact on Investments

Fusion Antibodies's employee data impacts investment decisions by shedding light on the company’s operational efficiency, innovation capability, and sustainability. Investors assess workforce data to gauge the firm's potential to execute strategies, innovate, and adapt to market changes effectively.

Interpreting Employee Trends

Fluctuations in Fusion Antibodies’s employee numbers indicate changes in business strategy, operational demands, and market dynamics. Investors and analysts scrutinize these trends to evaluate the company’s strategic positioning, adaptability, and potential for sustainable growth.

Frequently Asked Questions about Fusion Antibodies stock

How many employees does Fusion Antibodies have this year?

Fusion Antibodies has 47 undefined employees this year.

How many employees did Fusion Antibodies have compared to the previous year?

Compared to the previous year, Fusion Antibodies had 0% more employees.

What impact did the number of employees have on the company Fusion Antibodies?

The number of employees has a direct impact on the efficiency and productivity of Fusion Antibodies. A higher number of employees can indicate that the company is growing and has more resources to achieve its goals, while a lower number of employees may suggest that the company is saving costs or facing difficulties in recruiting new employees.

What impact did the number of employees have on investors of Fusion Antibodies?

The number of employees can also have an impact on investors of Fusion Antibodies, as it can be an indicator of the company's growth and financial health. A higher number of employees can promise investors, while a lower number of employees may raise concerns.

How does an increase in equity capital of Fusion Antibodies affect the company?

An increase in equity of Fusion Antibodies can improve the financial strength of the company and increase its ability to make future investments and fulfill obligations.

How does a reduction in Fusion Antibodies's equity affect the company?

A reduction in equity of Fusion Antibodies can impair its financial stability and decrease its ability to fulfill future investments and obligations.

What are some factors that influence the equity of Fusion Antibodies?

Some factors that can influence the equity of Fusion Antibodies include, among others, revenue development, profit and loss statement, dividend payments, and investments.

Why is the equity of Fusion Antibodies so important for investors?

The equity of Fusion Antibodies is important for investors as it is an indicator of the company's financial stability and provides investors with information on the amount of financial backing the company has in terms of obligations and future investments.

How does the number of employees at Fusion Antibodies influence the company?

The number of employees at Fusion Antibodies can directly impact the growth and performance of the company. A higher number of employees can lead to increased capacity and productivity, while a lower number of employees may result in reduced efficiency and limitations.

How has the number of employees at Fusion Antibodies evolved in recent years?

In recent years, the number of employees at Fusion Antibodies has changed by 0.

How many employees does Fusion Antibodies currently have?

Fusion Antibodies currently has 47 undefined employees.

Why is the number of employees important for investors of Fusion Antibodies?

The number of employees is important for investors of Fusion Antibodies as it is an indicator of the growth potential and performance of the company. It also provides information on how the company is able to manage and recruit its workforce.

What strategic measures can Fusion Antibodies take to change the number of employees?

To change the number of employees, Fusion Antibodies can take various measures such as adjusting compensation packages, improving working conditions, conducting recruitment campaigns, and promoting a positive corporate culture. It is important for the company to conduct a thorough assessment of its situation to determine the best strategic actions to change its number of employees.

How much dividend does Fusion Antibodies pay?

Over the past 12 months, Fusion Antibodies paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Fusion Antibodies is expected to pay a dividend of 0 GBP.

What is the dividend yield of Fusion Antibodies?

The current dividend yield of Fusion Antibodies is .

When does Fusion Antibodies pay dividends?

Fusion Antibodies pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Fusion Antibodies?

Fusion Antibodies paid dividends every year for the past 0 years.

What is the dividend of Fusion Antibodies?

For the upcoming 12 months, dividends amounting to 0 GBP are expected. This corresponds to a dividend yield of 0 %.

In which sector is Fusion Antibodies located?

Fusion Antibodies is assigned to the 'Health' sector.

Wann musste ich die Aktien von Fusion Antibodies kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Fusion Antibodies from 8/7/2024 amounting to 0 GBP, you needed to have the stock in your portfolio before the ex-date on 8/7/2024.

When did Fusion Antibodies pay the last dividend?

The last dividend was paid out on 8/7/2024.

What was the dividend of Fusion Antibodies in the year 2023?

In the year 2023, Fusion Antibodies distributed 0 GBP as dividends.

In which currency does Fusion Antibodies pay out the dividend?

The dividends of Fusion Antibodies are distributed in GBP.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Fusion Antibodies

Our stock analysis for Fusion Antibodies Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Fusion Antibodies Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.